Journal article
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty
Abstract
Importance: The efficacy of factor XIa inhibition for thromboprophylaxis is unknown. Osocimab is a long-acting, fully human monoclonal antibody that inhibits factor XIa.
Objective: To compare different doses of osocimab with enoxaparin and apixaban for thromboprophylaxis in patients who have undergone knee arthroplasty.
Authors
Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
Journal
JAMA: The Journal of the American Medical Association, Vol. 323, No. 2, pp. 130–139
Publisher
American Medical Association (AMA)
Publication Date
January 14, 2020
DOI
10.1001/jama.2019.20687
ISSN
0098-7484
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAntibodies, Monoclonal, HumanizedAnticoagulantsArthroplasty, Replacement, KneeDose-Response Relationship, DrugEnoxaparinFactor Xa InhibitorsFemaleHemorrhageHumansMaleMiddle AgedPostoperative ComplicationsPreoperative CarePulmonary EmbolismPyrazolesPyridonesSingle-Blind MethodVenous ThromboembolismVenous Thrombosis